The GLP-1 Access Puzzle: How Payers, CMS, & Employers Are Rewriting the Playbook

In 2026, the government became a major force in the GLP-1 market. Two CMS programs are reshaping who receives these drugs, what they cost, and how they reach patients—and they point in opposite directions at once. Meanwhile, commercial payers are economizing as more U.S. adults seek GLP-1 coverage. The result is a market pulling apart in real time, and manufacturers can no longer treat access as a single conversation.

Medicare's New Front Door: The GLP-1 Bridge

The Medicare GLP-1 Bridge went live on July 1, 2026. It is a temporary demonstration—now running through December 31, 2027—that puts a narrow set of FDA-approved obesity medications into the hands of eligible Part D beneficiaries for a flat $50 monthly copay.

The eligible drug list is tighter than most coverage of the program suggests: Wegovy (injection and tablets), Zepbound (KwikPen formulation only), and Foundayo, which was added in April 2026 following FDA approval. Single-dose vials and pens are excluded. This is not a general opening of the obesity class.

The design is unconventional. A single central processor—Humana—handles prior authorization, claims adjudication, and pharmacy payment, and the drugs sit entirely outside the standard Part D benefit. That means no deductible applies, the copay does not count toward True Out-of-Pocket (TrOOP) costs or the annual out-of-pocket cap, and there is no low-income subsidy (LIS) for LIS beneficiaries. The goal is straightforward: better quality of life for seniors for whom weight is a barrier to care.

One structural point that is widely misread: the Bridge exists only for weight-management use. Beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH are already eligible for GLP-1 coverage under standard Part D—and are therefore ineligible for the Bridge, even if they otherwise meet its clinical criteria. The Bridge is a workaround for the one indication Part D is barred by law from covering, not a broader benefit.

The number that matters most to manufacturers isn't $50. Under the Bridge, participating manufacturers supply eligible GLP-1s at a negotiated net price of $245 per monthly supply, where the beneficiary pays $50, and CMS covers the remaining $195. That figure is public, federal, and now the most visible reference price in the market.

The BALANCE Model: A Tale of Two Programs

The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) was meant to be the long game—a framework negotiated directly with manufacturers to lower prices and integrate GLP-1s into routine Part D and Medicaid coverage. The two programs were designed to hand off to each other: the Bridge would run six months, and BALANCE would take over Part D on January 1, 2027.

That handoff didn't happen. In an April 21, 2026 memo, CMS delayed the Medicare Part D portion of BALANCE indefinitely, pending further evaluation and data collection. Major Part D sponsors—including CVS and UnitedHealthcare—declined to participate voluntarily, citing concerns about the model's structure and costs, and the participation threshold went unmet. CMS responded by extending the Bridge through the end of 2027 and using it to collect utilization data it hopes will bring plans back to the table.

The Bridge got longer because BALANCE stalled. That causal link is the story: the temporary program is now the only Medicare pathway, and the permanent one has no announced restart date.

Medicaid is a different picture—but a more conditional one than headlines suggest. State Medicaid agencies can apply through July 31, 2026 and select a start date between May 1, 2026 and January 1, 2027, with the model running through December 2031. Participation is voluntary for states and manufacturers, so BALANCE guarantees coverage to no individual. And states are moving the other way: only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026, down from 16 in October 2025, after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage. The federal door opened just as states began walking out of it.

The Other Direction: Commercial Payers Pulling Back

Government action is only half the playing field. Commercial payers and PBMs are tightening in the other direction—formulary exclusions, stricter prior authorization, step therapy, and reauthorization tied to weight-loss milestones. Most state Medicaid policies now run stricter than the FDA label.

Some payers are dropping coverage entirely. At the start of 2026, Blue Cross Blue Shield of Massachusetts cut obesity GLP-1 coverage for employers under 100 employees, with Harvard Pilgrim, BCBS Michigan, and North Carolina Medicaid following.

Employers are split down the middle. Some self-insured plans are expanding GLP-1 coverage as a talent and health investment; others are carving it out or restricting eligibility as budgets strain.

The driver is cost. With list prices of $900–$1,400 per month and a large share of U.S. adults potentially eligible, GLP-1s already make up over 10% of annual claims in some employer plans, and expanding coverage could raise premiums meaningfully. In NFP's recent survey, 51% of employers named GLP-1s the top driver of rising drug costs. Yet demand keeps climbing even as affordability lags. Harder to cover, more sought after. That gap is the disconnect between payers and patients.

Why Payers Are Pulling Back

Behind the retrenchment are three pressing concerns:

1. The cost is too high. Millions of eligible patients paying four-figure monthly prices have pushed drug spending so high that premiums are climbing unsustainably. To protect other benefits, some plans are dropping weight-loss coverage altogether.

2. The payoff isn't showing up. A large share of patients discontinue GLP-1 treatment within the first year and often regain the weight, so payers aren't seeing the drop in other obesity-related claims they were counting on. One widely cited study found patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year.

3. The rules are getting stricter. Even when coverage stays, it comes with conditions: higher BMI cutoffs, required diet-and-exercise programs, or coverage limited to type 2 diabetes.

Several large U.S. employers plan to drop weight-loss coverage entirely next benefit year, pushing more patients to cash-pay. Direct-to-consumer programs and newer oral GLP-1s offer cheaper routes, but they remain far from affordable— the oral options start around $150 a month and injectables run higher. With these drugs still on-patent and no lower-cost competitors expected for years, prices aren't likely to fall soon.

Still, cutting coverage rarely means abandoning prevention. Most employers keep covering GLP-1s for diabetes and pair weight-loss cuts with lifestyle and behavioral programs, sometimes requiring patients to complete one before any drug coverage begins.

The 2027 Cliff

There is a deadline hiding inside all of this. The Bridge is a demonstration with no permanent statutory backing. Making obesity drug coverage permanent in Medicare would require congressional action, and BALANCE has no announced restart date for Part D.

That leaves an 18-month runway and no guaranteed landing. Several million beneficiaries could gain access this year and face an open question on January 1, 2028. For manufacturers, that is not a policy footnote—it is the planning horizon.

What This Means for Market Access Strategy

A single product must now succeed in four very different environments: a live federal demonstration, a voluntary state-by-state Medicaid model, a stalled Part D framework, and a commercial market moving the opposite way. Three priorities follow:

• Adapt the message to each audience. The case that wins coverage under Medicaid BALANCE is not the case that passes a commercial prior-authorization review. A one-size-fits-all pitch no longer works.

• Get ahead of the $245 net price—not just the $50 copay. The copay is what patients see; the federally negotiated net price is what commercial payers will bring to the negotiating table. Manufacturers who frame that number on their own terms will be far better positioned than those who react to it.

• Reach patients directly. GLP-1 demand is high regardless of coverage. Manufacturers need clear direct paths to patients—without straining payer relationships or handing insurers a reason to scale back further.

• Plan for December 2027 now. Whatever succeeds the Bridge will be shaped by the utilization data CMS is collecting today. Evidence generation during the demonstration is not a research exercise; it is the argument for what comes next.